Profile data is unavailable for this security.
About the company
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
- Revenue in USD (TTM)0.00
- Net income in USD-12.84m
- Incorporated2020
- Employees8.00
- LocationTiziana Life Sciences Ltd3Rd Floor, 11-12 St. James's SquareLONDON SW1Y 4LBUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://www.tizianalifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 165.61m | 31.00 | -- | 3.54 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 168.24m | 66.00 | -- | -- | -- | 87.31 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 168.69m | 140.00 | -- | 0.947 | -- | 1.49 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 168.86m | 97.00 | -- | 1.56 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 173.40m | 166.00 | -- | 0.6857 | -- | 6.45 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 173.76m | 246.00 | -- | 12.34 | -- | 3.75 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Tharimmune Inc | 0.00 | -10.32m | 175.82m | 2.00 | -- | 5.46 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 177.51m | 8.00 | -- | 18.21 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Galectin Therapeutics Inc | 0.00 | -37.44m | 177.94m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| C4 Therapeutics Inc | 30.11m | -119.08m | 178.32m | 110.00 | -- | 0.8839 | -- | 5.92 | -1.67 | -1.67 | 0.4225 | 2.08 | 0.0939 | -- | 3.57 | 273,709.10 | -37.12 | -26.50 | -42.35 | -29.90 | -- | -- | -395.51 | -310.19 | -- | -- | 0.00 | -- | 71.44 | 10.72 | 20.51 | -- | -33.16 | -- |
| MDxHealth SA | 103.07m | -31.43m | 179.18m | 312.00 | -- | -- | -- | 1.74 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 181.08m | 34.00 | -- | 6.96 | -- | 9.55 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 183.42m | 14.00 | -- | 1.54 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 187.40m | 6.00 | -- | 4.48 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Tiziana Life Sciences Ltd's reporting currency: US Dollar USD
3.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dauntless Investment Group LLCas of 30 Sep 2025 | 2.74m | 2.30% |
| Marshall Wace LLPas of 30 Sep 2025 | 268.01k | 0.23% |
| Millennium Management LLCas of 30 Sep 2025 | 240.81k | 0.20% |
| UBS Securities LLCas of 31 Dec 2025 | 105.22k | 0.09% |
| Zhang Financial LLCas of 30 Sep 2025 | 84.20k | 0.07% |
| Kovitz Investment Group Partners LLCas of 30 Sep 2025 | 79.37k | 0.07% |
| Geode Capital Management LLCas of 30 Sep 2025 | 78.20k | 0.07% |
| HSBC Bank Plc (Broker)as of 30 Sep 2025 | 75.37k | 0.06% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 61.53k | 0.05% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 51.25k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
